SEC Form 4 · accession 0001179110-17-005724
Assertio Therapeutics, Inc · ASRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew M Gosling
Officer — SVP, General Counsel
Period of report
Mar 31, 2017
Accepted (ET)
Apr 4, 2017 · 8:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005201
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Apr 2, 2017 | F | 940 | $12.55 | D | 79,877 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3,F4 | — | Mar 31, 2017 | A | 60,000 | A | — | — | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1Represents shares of restricted stock forfeited to meet the tax liability triggered by the vesting of such restricted stock.
- F2Amount does not include any unvested restricted stock previously reported on Form 4 by the reporting person.
- F3Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.
- F4These restricted stock units are scheduled to vest 50% on March 31, 2018 and 50% on March 31, 2019, assuming continued employment through the applicable vesting date.